Aspirin was developed in 1897 but, despite many years of widespread use, the full therapeutic potential of acetylsalicylic acid (ASA) is still being uncovered and important uncertainties remain about its therapeutic role. Its efficacy in secondary prevention of cardiovascular disease is unchallenged but a recent meta-analysis has prompted questions about the place of low-dose aspirin as primary prevention of cardiovascular disease - in particular, about the balance of risk and benefit in people with diabetes.Some people do not derive the expected benefit from aspirin prophylaxis but we do not fully understand why this is the case.This roundtable meeting, convened by the Aspirin Foundation and the British Journal of Cardiology, was sponsored by Bayer Health Care. It reviewed current knowledge about the role of aspirin in the management of cardiovascular disease.
展开▼
